Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV

Company to Develop Gene Editing Therapies to Permanently Reduce Risk of Coronary Artery Disease in Adults

Announces Key Licensing Agreements with the Broad Institute and Harvard University, and Collaboration Agreements with Beam Therapeutics and Verily

Leading Cardiologist and Geneticist Sekar Kathiresan, M.D., Named Chief Executive Officer

CAMBRIDGE, Mass., May 7, 2019-- Verve Therapeutics, a next-generation cardiovascular company, today announced its launch to discover and develop therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary …